Mironid closed a €39.9 million Series B financing on 5 August 2026. The round was led by the Scottish National Investment Bank and includes Roche Venture Fund and Epidarex Capital.
Mironid, a biopharmaceutical company headquartered in Glasgow, United Kingdom, announced the completion of a €39.9 million (approximately $46 million) Series B funding round on 5 August 2026. The announcement was reported by multiple outlets on 7–8 August 2026. The capital will be directed toward clinical development of Mironid’s small‑molecule candidate for autosomal dominant polycystic kidney disease (ADPKD), a rare hereditary condition that leads to progressive kidney failure.
The financing round involved three principal investors: the Scottish National Investment Bank (SNIB) acted as lead investor, while Roche Venture Fund and Epidarex Capital participated as co‑investors. Mironid, founded in 2015, has focused on rare kidney‑disease therapeutics and reported that the new funds will support pre‑clinical validation, regulatory submissions, and Phase II/III clinical trials for its ADPKD candidate.
The round was structured as a Series B equity financing, with standard preferred‑share terms typical for late‑stage biotech investments.
Funding Structure and Investor Participation
The €39.9 million Series B round was organized through a private placement of preferred shares to institutional investors. SNIB contributed the majority of the capital, reflecting its mandate to stimulate Scottish life‑science innovation. Roche Venture Fund, the venture‑capital arm of Roche Holding AG, added strategic biotech expertise, while Epidarex Capital, a UK‑based life‑science investor, provided additional growth capital.
The financing terms included a right of first refusal on future equity rounds, a clause common in biotech financing to preserve investor influence over subsequent development stages.
Each investor received customary anti‑dilution protections and board observer rights, aligning their interests with Mironid’s long‑term value creation goals. The financing terms included a right of first refusal on future equity rounds, a clause common in biotech financing to preserve investor influence over subsequent development stages.
Mironid’s leadership, including CEO Dr. Alistair McLeod, indicated that the capital infusion will extend the company’s cash runway through at least 2029, enabling the execution of a comprehensive clinical development plan without immediate reliance on additional fundraising.
Clinical Development Plan for ADPKD
Glasgow Biotech Firm Mironid Secures €39.9 Million Series B to Advance ADPKD Therapy
Mironid’s ADPKD program centers on a novel small‑molecule inhibitor designed to reduce cyst formation and slow renal function decline. The company has completed pre‑clinical toxicology studies and is preparing an Investigational New Drug (IND) application for submission to the European Medicines Agency (EMA) in Q4 2026.
The Delhi Cabinet approved a draft law authorizing private and foreign institutions to operate as universities, with a 25% seat reservation for Delhi residents, and…
The Series B proceeds will fund a Phase II clinical trial enrolling approximately 120 patients across Europe and North America, with primary endpoints focused on total kidney volume reduction and estimated glomerular filtration rate (eGFR) preservation. Contingent on Phase II outcomes, Mironid plans to initiate a pivotal Phase III trial in 2028, targeting regulatory approval in the EU and United States by 2031.
The company also announced collaborations with leading nephrology research centers, including the University of Glasgow’s Institute of Cardiovascular and Medical Sciences, to access patient registries and accelerate enrollment. These partnerships are intended to enhance data robustness and support future health‑economic assessments of the therapy.
Immediate Impact on Stakeholders
For patients with ADPKD and their families, the secured funding represents a tangible step toward a disease‑modifying treatment that is currently unavailable in standard care pathways. Healthcare providers may anticipate new clinical trial sites opening in Glasgow and surrounding regions, offering patients early access to investigational therapy.
These partnerships are intended to enhance data robustness and support future health‑economic assessments of the therapy.
Biotech educators and students in the United Kingdom can observe a concrete example of regional investment mechanisms—such as the SNIB—supporting translational research, potentially influencing curricula that emphasize public‑sector venture financing.
Pharmaceutical companies operating in the rare‑disease space may view Mironid’s financing round as an indicator of continued investor appetite for early‑stage renal‑disease pipelines, informing corporate development strategies and partnership considerations.
Key Facts
What: Mironid closed a €39.9 million Series B round to fund ADPKD drug development.
When: Funding round closed 5 August 2026; reported 7–8 August 2026.
Cloudflare introduced Kitesurf, a cloud-hosted browser for AI agents, alongside tools that give those agents a verifiable identity and a secure digital wallet.
NewsNews
